Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors at 1 institution in 1 country.
Yi PengProgram for Lung and Vascular Biology, and Section for Injury Repair and Regeneration Research, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
Jingbo DaiProgram for Lung and Vascular Biology, and Section for Injury Repair and Regeneration Research, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.ORCID 0000-0001-7562-9039
You-Yang ZhaoProgram for Lung and Vascular Biology, and Section for Injury Repair and Regeneration Research, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.ORCID 0000-0002-0041-0339
Northwestern University · US
Funding
Novel mechanisms of obliterative pulmonary vascular remodeling and sever pulmonary arterial hypertensionR01HL133951 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZHAO, YOU-YANG · 2016 to 2024
$4.9M
Negative regulators of endothelial regeneration in aging lungs and ARDSR01HL164014 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.7M
Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAHR01HL162299 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.6M
Novel mechanisms of endothelial Injury in the pathogenesis of ARDSR01HL148810 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2020 to 2023
$2.3M
National Heart Lung and Blood Institute R01HL133951National Heart Lung and Blood Institute R01HL148810National Heart Lung and Blood Institute R01HL162299National Heart Lung and Blood Institute R01HL164014NHLBI NIH HHS R01 HL133951NHLBI NIH HHS R01 HL148810NHLBI NIH HHS R01 HL162299NHLBI NIH HHS R01 HL164014
6 · The paper itself
Abstract
Pulmonary arterial hypertension (PAH) is a progressive and inevitably fatal disease characterized by the progressive increase of pulmonary vascular resistance and obliterative pulmonary vascular remodeling, which lead to right-sided heart failure and premature death. Many of the genetically modified mouse models do not develop severe PH and occlusive vascular remodeling.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.